Amphivena raises $62M Series C round to develop bispecific antibody in solid tumors
The company presented data from a Phase I study in acute myeloid leukemia at the European Hematology Association's annual meeting during the summer.
AMV564
The company presented data from a Phase I study in acute myeloid leukemia at the European Hematology Association's annual meeting during the summer.